Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Kostenloser Versand möglich
Kostenloser Versand möglich
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
Real-World Evidence in Drug Development and Evaluation
ISBN/GTIN

Real-World Evidence in Drug Development and Evaluation

BuchKartoniert, Paperback
Verkaufsrang7315inMedizin
CHF71.50

Beschreibung

This book concerns use of real world data (RWD) and real world evidence (RWE) to aid drug development across product cycle. RWD are healthcare data that are collected outside the constraints of conventual controlled randomized trials (CRTs); whereas RWE is the knowledge derived from aggregation and analysis of RWD.
Weitere Beschreibungen

Details

ISBN/GTIN978-0-367-63701-9
ProduktartBuch
EinbandKartoniert, Paperback
Erscheinungsdatum29.08.2022
Auflage1. A.
ReiheChapman & Hall/CRC Biostatistics Series
Seiten178 Seiten
SpracheEnglisch
MasseBreite 156 mm, Höhe 234 mm, Dicke 11 mm
Gewicht285 g
IllustrationenFarb., s/w. Abb.
Artikel-Nr.20841898
KatalogBuchzentrum
Datenquelle-Nr.39046374
Weitere Details

Reihe

Bewertungen

Autor

Harry Yang, Ph.D., is Vice President and Head of Biometrics at Fate Therapeutics. He has 25 years of experience across all aspects of drug research and development, from early target discovery, through pre-clinical, clinical, and CMC programs to regulatory approval and post-approval lifecycle management. He has published 7 statistical books, 15 book chapters, and over 90 peer-reviewed papers on diverse scientific and statistical subjects. He is a frequent invited speaker at national and international conferences. He also developed statistical courses and conducted training at the FDA and USP.

Binbing Yu, Ph.D., is Associate Director in the Oncology Statistical Innovation group at AstraZeneca. He serves as the statistical expert across the whole spectrum of drug R&D, including drug discovery, clinical trials, operation and manufacturing, clinical pharmacology, oncology medical affairs and post-marketing surveillance. He obtained his PhD in Statistics from the George Washington University. His primary research interests are clinical trial design and analysis, cancer epidemiology, causal inference in observation studies, PKPD modeling and Bayesian analysis.